Oxaliplatin - CAS 61825-94-3
Catalog number:
B0084-095706
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C8H14N2O4Pt
Molecular Weight:
397.29
COA:
Inquire
Targets:
DNA Alkylator/Crosslinker
Description:
Oxaliplatin is a platinum-based antineoplastic agent used in cancer chemotherapy that inhibits DNA synthesis by conforming DNA adducts in cancer cells.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-095706 500 mg $196 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
antineoplastic agent
Purity:
>98%
Appearance:
Crystalline solid
Synonyms:
LY-237216, ASE 136; (SP-4-2)-[1R,2R-cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]-platinum
MSDS:
Inquire
Application:
antineoplastic agent
InChIKey:
ZROHGHOFXNOHSO-UHFFFAOYSA-L
InChI:
InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2
1. Novel potassium N-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxylhex-1-yl]-L-amino acid dichloroplatinates(II) with high anti-tumor activity and low side reaction
Yuji Wang, Guifeng Kang, Jiawang Liu, Ming Zhao,* Shiqi Peng*. Metallomics, 2012, 4, 441–447
To evaluate the anti-tumor activities of 5a–c, in vitro anti-proliferation assays were performed on HeLa, HL-60, and S180 cell lines, in accordance with the standard MTT method, and cisplatin and oxaliplatin were used as positive controls. The in vitro anti-proliferation activities of 5a–c,cisplatin and oxaliplatin were evaluated at a series of concentrations ranging from 0.004 mM to 400 mM. The IC50 values of cisplatin, oxaliplatin and 5a–c inhibiting the HeLa, HL-60, and S180 cell lines are shown in Fig.2.
2. Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer
James P. Parker, Ziga Ude and Celine J. Marmion*. Metallomics, 2016, 8, 43—60
Oxaliplatin is currently used to treat certain (wild-type KRAS) metastatic colorectal cancers expressing epidermal growth factor receptor (EGFR) in combination with the monoclonal antibody Cetuximab. Garrido et al. successfully linked Cetuximab to oxaliplatin-loaded EGFR-targeted liposomes in a pioneering study. This facilitated the selective delivery of both drug entities in a single therapeutic approach. The liposomes demonstrated enhanced tumour drug accumulation as compared to free oxaliplatin or a non-targeted liposome as well as having improved efficacy in mice inoculated with a colorectal cancer cell line which over expresses this receptor.
3. Oxaliplatin vs. cisplatin: competition experiments on their binding to lysozyme
Daniela Marasco, Luigi Messori, Tiziano Marzoc and Antonello Merlino*. Dalton Trans.,2015, 44,10392–10398
These arguments prompted us to investigate the formation of the adducts that are obtained when oxaliplatin and cisplatin are incubated with HEWL. These results are of potential interest if one considers that cisplatin and oxaliplatin might be clinically used in combination and that studies of the cisplatin/oxaliplatin combination on patients with advanced ovarian cancer already revealed acceptable hematologic toxicity, and reversible cumulative neurosensory toxicity. Simultaneous injection of cisplatin and oxaliplatin was reported to produce a synergistic antitumor activity against cisplatin-resistant murine leukemia L1210.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related DNA Alkylator/Crosslinker Products


CAS 31645-39-3 Palifosfamide

Palifosfamide
(CAS: 31645-39-3)

Palifosfamide is a synthetic mustard compound with potential antineoplastic activity. An active metabolite of ifosfamide covalently linked to the amino acid lys...

CAS 61825-94-3 Oxaliplatin

Oxaliplatin
(CAS: 61825-94-3)

Oxaliplatin is a platinum-based antineoplastic agent used in cancer chemotherapy that inhibits DNA synthesis by conforming DNA adducts in cancer cells.

Cgp 6809
(CAS: 84069-38-5)

Cgp 6809 is a new methylnitrosoureido-sugar derivative. It is active against a broad spectrum of transplantable tumours in mice and rats. But Phase I clinical t...

CAS 85622-93-1 Temozolomide

Temozolomide
(CAS: 85622-93-1)

Temozolomide is an oral chemotherapy drug.The therapeutic benefit of temozolomide depends on its ability to alkylate/methylate DNA, which most often occurs at t...

CAS 645-05-6 Altretamine

Altretamine
(CAS: 645-05-6)

Altretamine is an anti-neoplastic agent.

CAS 3778-73-2 Ifosfamide

Ifosfamide
(CAS: 3778-73-2)

Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer.

CAS 41575-94-4 Carboplatin

Carboplatin
(CAS: 41575-94-4)

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism.

CAS 154-93-8 Carmustine

Carmustine
(CAS: 154-93-8)

Carmustine is  antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA fun...

CAS 92118-27-9 Fotemustine

Fotemustine
(CAS: 92118-27-9)

Fotemustine is a chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of gu...

CAS 50-18-0 Cyclophosphamide

Cyclophosphamide
(CAS: 50-18-0)

Low-dose preferentially deplets Treg cells; An alkylating agent of the nitrogen mustard type with antineoplastic and immunosuppressive activities; Phase I–II

CAS 299-75-2 Treosulfan

Treosulfan
(CAS: 299-75-2)

Treosulfan is the prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppresive, and antineoplastic activities. Under physiological ...

Altretamine hydrochloride
(CAS: 2975-00-0)

Altretamine hydrochloride, also called as hexamethylmelamine hydrochloride, is an alkylating agent with apparently less toxicity compared to other cytotoxic dru...

CAS 13010-47-4 Lomustine

Lomustine
(CAS: 13010-47-4)

Lomustine (420 μM) triggers apoptosis through the mitochondrial pathway via decrease in the level of the anti-apoptosis proteins Bcl-2 and Bcl-xl, respectively.

CAS 23261-20-3 VAL-083

VAL-083
(CAS: 23261-20-3)

VAL-083 is a bi-functional alkylating agent; inhibit U251 and SF188 cell growth in monolayer better than TMZ and caused apoptosis.

CAS 15663-27-1 Cisplatin

Cisplatin
(CAS: 15663-27-1)

Cisplatin induces cytotoxic by interaction with DNA to form DNA adducts which activate several signal transduction pathways, including Erk, p53, p73, and MAPK, ...

CAS 18883-66-4 Streptozotocin

Streptozotocin
(CAS: 18883-66-4)

Streptozotocin is a glucosamine-nitrosourea derivative, which is a methylating, carcinogenic, antibiotic and diabetes inducing agent. It is commonly used for th...

CAS 55-98-1 Busulfan

Busulfan
(CAS: 55-98-1)

Busulfan is a cell cycle non-specific alkylating antineoplastic agent.

CAS 232931-57-6 SJG-136

SJG-136
(CAS: 232931-57-6)

SJG136 is a pyrrolobenzodiazepine dimer with potential antineoplastic activity. SJG-136 binds to the minor groove of DNA and induces interstrand cross-links bet...

CAS 129580-63-8 Satraplatin

Satraplatin
(CAS: 129580-63-8)

Satraplatin, also known as JM216, is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who ha...

Chemical Structure

CAS 61825-94-3 Oxaliplatin

Quick Inquiry

Verification code

Featured Items